Summary & Overview
Other Endovascular Cardiac Valve Procedures without MCC: Inpatient Reimbursement Overview
DRG 320 encompasses inpatient stays for other endovascular cardiac valve procedures without Major Complication or Comorbidity, focusing on percutaneous and transcatheter valve interventions that do not have major complications. This grouping matters for inpatient reimbursement because it standardizes payment for cases with similar resource needs under the Medicare prospective payment system.
DRG 320 Overview
DRG 320 covers hospital admissions for other endovascular cardiac valve procedures without Major Complication or Comorbidity. These procedures include transcatheter valve interventions and other percutaneous techniques that do not meet Major Complication or Comorbidity status. This Diagnosis-Related Group is important for Medicare payment because it groups similar resource use for prospective inpatient reimbursement. Accurate coding of procedures and comorbid conditions determines assignment to this Diagnosis-Related Group and affects payment.
Clinical Trials
- Acute procedural optimization studies: trials that evaluate intra-procedural techniques, imaging guidance strategies, or alternative access approaches for endovascular cardiac valve procedures in hospitalized patients without major complications. These studies enroll patients undergoing transcatheter valve repair or replacement for isolated valvular disease (for example severe aortic or mitral stenosis/regurgitation) and compare procedural endpoints such as device deployment success, procedural time, and immediate hemodynamic improvement. Results are relevant to providers and payers because improved procedural efficiency and reduced intraoperative resource use can lower hospital LOS and procedural costs while maintaining quality of care for this DRG group.
- Comparative effectiveness research of device or strategy choice: randomized or pragmatic observational studies comparing different valve prostheses, repair devices, or anticoagulation/antiplatelet regimens in patients eligible for endovascular valve intervention without major comorbidity. These studies focus on mid-term outcomes such as paravalvular leak rates, need for reintervention, readmission, and functional status over months to a year, enrolling typical inpatient candidates for minimally invasive valve therapy. Findings inform clinicians and payers about which devices or peri-procedural management strategies provide the best balance of clinical benefit and cost-effectiveness for patients classified under this DRG.
- Post-discharge outcomes and care pathway studies: cohort studies and quality improvement trials examining transitional care, rehabilitation, and readmission prevention in patients discharged after uncomplicated endovascular valve procedures. Research evaluates predictors of early readmission, outpatient monitoring protocols, and patient-reported outcomes (symptoms, mobility, and quality of life) in this relatively lower-acuity DRG population. These data help hospitals and payers design targeted discharge planning and follow-up that reduce avoidable readmissions and resource utilization while supporting recovery.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.